Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates

Corcept Therapeutics Incorporated (CORT) reported first-quarter 2024 earnings of 25 cents per share, which beat the Zacks Consensus Estimate of 21 cents. The company had reported earnings of 14 cents per share in the year-ago quarter.Revenues increased 39% year over year to $146.8 million. The figure beat the Zacks Consensus Estimate of$138 million. The top line solely comprises product sales of Cushing’s syndrome drug, Korlym.Quarter in DetailRevenues from Korlym beat our model estimate of $129.8 million. ...